Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.
Inès BoussenMaud SalmonaFlore Sicre De FontbruneAliénor XhaardNathalie De CastroConstance DelaugerreMarie-Laure ChaixJean-Michel MolinaPublished in: Antiviral therapy (2024)
We report the case of an allogeneic stem cell transplant recipient with nosocomial acquisition of SARS-CoV-2 infection who received antispike neutralizing monoclonal antibody bamlanivimab 2 days after diagnosis of SARS-CoV-2 infection but progressed to severe COVID-19 pneumonia and died with the selection of E484K/Q resistance mutations to bamlanivimab.
Keyphrases
- stem cells
- monoclonal antibody
- respiratory syndrome coronavirus
- stem cell transplantation
- sars cov
- coronavirus disease
- bone marrow
- acinetobacter baumannii
- hematopoietic stem cell
- methicillin resistant staphylococcus aureus
- klebsiella pneumoniae
- high dose
- cell therapy
- low dose
- mesenchymal stem cells
- multidrug resistant
- escherichia coli
- drug induced